LegoChem Bioscience said that it has designated WuXi AppTec, a Chinese contract research organization, to provide non-clinical trial services for its products.

LegoChem Bioscience CEO Kim Yong-joo (left) and WuXi AppTec Korea Director Cho Seok-young hold up their agreement, at LegoChem Bioscience headquarters in Daejeon, on Wednesday.

"Founded in 2000, WuXi AppTec supports the entire process of preclinical drug development worldwide, including China, the U.S., Europe, and the rest of the Asia-Pacific region," the company said. "It is a global company that has provided the highest level of service to numerous multinational biopharmaceutical companies."

Under the accord, LegoChem, which has various drug candidates, including an antibody drug conjugate (ADC) and Covid-19 treatment, will receive WuXi AppTec's one-stop service for all the necessary procedures for submitting investigational new drug (IND) application, the company said.

"Through this agreement, we plan to establish a global clinical entry bridge for our new ADC drugs based on state-of-the-art facilities and unique preclinical expertise possessed by WuXi AppTec," LegoChem Bioscience CEO Kim Yong-joo said. "We will enter the clinical trials of newly introduced COVID-19 treatment quickly."

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>